Intranasal Protollin(Trademark)/F1-V Vaccine Elicits Respiratory and Serum Antibody Responses and Protects Mice Against Lethal Aerosolized Plague Infection
Abstract
F1-V is a recombinant plague antigen comprising the capsular (F1) and virulence-associated (V) proteins. Given intramuscularly with Alhydrogel, it protects mice against challenge, but is less effective in non-human primates against high-dose aerosolized Yersinia pestis challenge, perhaps because it fails to induce respiratory immunity. Intranasal immunization of mice with F1-V formulated with a Proteosome-based adjuvant (Protollin trademark), elicited high titers of specific IgA in lungs whereas intranasal F1-V alone or intramuscular Alhydrogel-adsorbed F1-V did not. The Protollin-adjuvanted F1-V vaccine also induced high serum titers of specific IgG, comparable to those induced by intramuscular Alhydrogel-adsorbed F1-V. Mice immunized intranasally with Protollin-F1-V were 100% protected against aerosol challenge with 170 LD50 of Y. pestis and 80% against 255 LD50.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 07, 2005
- Accession Number
- ADA449365
Entities
People
- Chris R. Bolt
- David S. Burt
- George H. Lowell
- Jeffrey J. Adamovicz
- Louise M. Pitt
- Nathalie Bellerose
- Sonya L. Cyr
- Taff Jones